Positive<\/p>\n
+14.8%<\/p>\n
Initiated Phase IIb trial site for SCI-110 at Hannover Medical School<\/p>\n
Jun 04<\/p>\n
Acquisition completion<\/a><\/p>\n Positive<\/p>\n +22.0%<\/p>\n Completed acquisition of approximately 54% of CliniQuantum through subsidiary NeuroThera Labs<\/p>\n May 28<\/p>\n Acquisition approval<\/a><\/p>\n Positive<\/p>\n +140.3%<\/p>\n Received conditional TSX Venture Exchange approval to acquire approximately 54% of CliniQuantum<\/p>\n Mar 16<\/p>\n Patent application<\/a><\/p>\n Positive<\/p>\n -0.9%<\/p>\n Collaboration produced a Hong Kong patent application for depression therapy<\/p>\n Mar 12<\/p>\n Patent publication<\/a><\/p>\n Positive<\/p>\n +22.9%<\/p>\n Published international patent application targeting weight loss and fatty liver disease<\/p>\n Pattern Detected<\/p>\n Four of five comparable prior announcements were followed by positive 24-hour reactions, while one produced a slight decline.<\/p>\n agentic artificial intelligence<\/p>\n technical<\/p>\n “decision to target the agentic artificial intelligence (\u201cAI\u201d) market”<\/p>\n A type of artificial intelligence that can set goals, make decisions, and carry out multi-step actions across digital or physical systems with limited human direction\u2014think of it as an autonomous employee that plans and executes tasks. Investors care because agentic AI can boost productivity and create new revenue streams by automating complex work, but it also introduces risks (unexpected behavior, higher development costs, and regulatory scrutiny) that can affect company value and future cash flows.<\/p>\n AI-generated analysis. How Rhea-AI works<\/a>. Not financial advice.<\/p>\n
TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC<\/a>) (\u201cCompany\u201d or \u201cSciSparc\u201d), today announced that its board of directors has made a decision to target the agentic artificial intelligence (\u201cAI\u201d) market.<\/p>\n As part of this initiative, the Company has decided to establish a Scientific Advisory Board to focus on AI and cybersecurity. SciSparc is currently evaluating opportunities and is in discussions with several companies active in the agentic AI field.<\/p>\n About SciSparc Ltd. (Nasdaq: SPRC<\/a>):<\/p>\n The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc\u2019s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and\/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI- 210 for the treatment of Autism Spectrum Disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the\u00a0Amazon.com<\/a>\u00a0Marketplace.<\/p>\n Forward-Looking Statements:<\/p>\n This press release contains forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the opportunities available to it in the agentic AI market. However, the Company may ultimately not identify any opportunities in the agentic AI field and may not ultimately realize the opportunities contemplated by the formation of the Scientific Advisory Board. Because such statements deal with future events and are based on SciSparc\u2019s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading \u201cRisk Factors\u201d in SciSparc\u2019s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.<\/p>\n
\n
\n
\n
\n
\n
<\/p>\n![\"\"](\"https:\/\/static.stocktitan.net\/img\/icons\/Google_News_icon.svg\"){kind=icon}
<\/p>\n
\n
\n See more from StockTitan in Google Search and AI answers.
\n Adds StockTitan as a preferred source \u00b7 opens Google
\n <\/p>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n 07\/27\/2026 – 08:25 AM
\n
\n
<\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/ai\/wp-content\/uploads\/2026\/07\/1785194903_481_ti.gif\"\/)
![\"\"](\"https:\/\/www.europesays.com\/ai\/wp-content\/uploads\/2026\/07\/SciSparc-Ltd.png\")